Impact News +++ KeyBanc Flags AeroVironment (AVAV) as Top Iran Conflict Winner (24/7 Wall St.) +++ AEROVIRONMENT Aktie +3,22%

QUOIN Aktie

>QUOIN Aktienkurs

7.419 EUR (TradegateBSX)

Ask: 7.613 EUR / 1350 Stück

Bid: 7.224 EUR / 1400 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

QUOIN Aktie über LYNX handeln

Intraday

1 Jahr

>QUOIN Performance

1 Woche: -2,4%

1 Monat: +16,2%

3 Monate: -41,1%

6 Monate: +20,9%

1 Jahr: 0%

laufendes Jahr: -39,5%

>QUOIN Aktie

Name:

QUOIN PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US74907L4095 / A41BEM

Symbol/ Ticker:

2EB0 (Frankfurt) / QNRX (NASDAQ)

Kürzel:

FRA:2EB0, ETR:2EB0, 2EB0:GR, NASDAQ:QNRX

Index:

Webseite:

https://quoinpharma.com/

Profil:

Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing therapeutic products targeting rare and orphan diseases. Its diversified pro..
>Volltext..

Marktkapitalisierung:

4.27 Mio. EUR

Unternehmenswert:

-0.39 Mio. EUR

Umsatz:

EBITDA:

-12.21 Mio. EUR

Nettogewinn:

-11.94 Mio. EUR

Gewinn je Aktie:

-404.65 EUR

Schulden:

Liquide Mittel:

1.58 Mio. EUR

Operativer Cashflow:

-9.32 Mio. EUR

Bargeldquote:

0.94

Umsatzwachstum:

Gewinnwachstum:

-58.44%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

QUOIN

Letzte Datenerhebung:

11.03.26

>QUOIN Kennzahlen

Aktien/ Unternehmen:

Aktien: 0.59 Mio. St.

Frei handelbar: -

Leerverk. Aktien: -

Rückkaufquote: -126.76%

Mitarbeiter: 5

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 214.42%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -155.64%

Eigenkaprendite: -655.85%

>QUOIN Peer Group

Gesundheit

>QUOIN Chart & Kurs - NASDAQ

>QUOIN News

11.03.26 - 13:33	Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome (GlobeNewswire EN)
	— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need —...

27.01.26 - 14:33	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome (GlobeNewswire EN)
	Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status...

20.01.26 - 14:33	Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome (GlobeNewswire EN)
	Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome...

11.11.25 - 15:30	Quoin Pharmaceuticals: Aktie springt nach Meilenstein bei Rapamycin-Formulierung um 66 % (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 14:33	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies (GlobeNewswire EN)
	Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively...

06.11.25 - 14:33	Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results (GlobeNewswire EN)
	– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D...

04.11.25 - 21:30	Prysmian Hosts Ribbon Cutting Ceremony to Unveil $63.8M Du Quoin Facility Expansion (Accesswire)
	DU QUOIN, IL / ACCESS Newswire / November 4, 2025 / Prysmian, a world leader in the energy transition and digital transformation, recently held a ribbon cutting ceremony to officially unveil the co......

30.10.25 - 13:33

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 (GlobeNewswire EN)

ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the third quarter ended September 30, 2025, before the market opens on Thursday, November 6, 2025....

28.10.25 - 14:18	Quoin Pharmaceuticals: Aktie steigt nach positiven Daten aus pädiatrischer Studie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

21.10.25 - 14:33	Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome (GlobeNewswire EN)
	Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US...

16.10.25 - 03:01	Insiderhandel: Aufsichtsrat kauft Aktien von Quoin Pharmaceuticals im Wert von 128640 USD (Insiderkauf)
	Langer, Dennis - Aufsichtsrat - Tag der Transaktion: 2025-10-14...

10.10.25 - 16:06	Quoin Pharmaceuticals: Aktie explodiert nach Finanzierungszusage mit Preisaufschlag (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.10.25 - 15:36	Quoin Pharmaceuticals announces private placement financing of up to $104.5M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.10.25 - 15:27

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million (GlobeNewswire EN)

PIPE financing included participation from leading healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others PIPE financing included participation from leading healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others...

09.09.25 - 14:33	Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome (GlobeNewswire EN)
	New Episode Highlights the Social and Emotional Impact of Netherton Syndrome, the Importance of Supportive Communities, and the Urgent Need for an Approved Treatment New Episode Highlights the Social and Emotional Impact of Netherton Syndrome, the Importance of Supportive Communities, and the Urgent Need for an Approved Treatment...

21.08.25 - 14:33	Quoin Pharmaceuticals′ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome (GlobeNewswire EN)
	ASHBURN, Va., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that its NETHERTON NOW awareness campaign has surpassed a major milestone, achieving more than one million video views and over 14 million impressions....

18.08.25 - 14:39	Quoin Pharmaceuticals appoints Sally Lawlor as CFO (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

18.08.25 - 14:33

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy (GlobeNewswire EN)

ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization....

12.08.25 - 14:33	Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton (GlobeNewswire EN)
	New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective Treatments New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective Treatments...

08.08.25 - 06:48	Quoin (QNRX) Q2 Loss Beats Estimates (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer alle Macht hat, muß auch alles fürchten. - Pierre Corneille

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram